Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION

Award Number: R21CA131522
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2008
PERIOD OF PERFORMANCE END DATE: 06/30/2011

Group Awards By:

View Award Description

FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION - DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is, at present, incurable preleukemic disease occurring most frequently among the elderly with about 14,000 new cases per year in the USA. About 30-40% of these cases progress to acute myeloid leukemia (AML). With an urgent need to improve therapy in this group, it is critical to generate effective modeling systems (including mouse models) for investigating the genetic lesions commonly observed in MDS and AML. However, the precise molecular mechanisms whereby genetic changes induce the progression of MDS to AML remain poorly understood. The proposed research focuses on an innovative mouse model for studying MDS progression and AML transformation through the somatic delivery of avian retroviruses that encode hyperactive KRAS and NRAS to transgenic mice. These mice have been engineered to bear the retroviral receptor, TVA, specifically within the hematopoietic stem cells that express an oncogene, SALL4B. We recently have identified this new oncogene and have discovered that overexpression of SALLB in mice exhibits MDS at age two months and, subsequently, displays AML transformation with a long latency. We hypothesize that additional mutations are required to activate a proliferative pathway, such as the RAS gene signaling pathway, to cause the SALL4B oncogene to mediate the transformation of MDS to AML. To test our hypothesis, RAS- encoding retroviruses will be delivered to mouse bone marrow where the SALL4B oncogene is overexpressed. Through our mouse model, we will characterize the cooperativity between hyperactive RAS with the SALL4B oncogene. The proposed studies will advance our understanding of the molecular events associated with MDS progression and AML transformation. An important outcome of our research with this innovative mouse model lies in the potential for developing effective target therapies for MDS thus improving the prognosis for patients facing this incurable disease. Such an advancement presents significant benefits to public health by reducing the high rate of mortality associated with MDS. PUBLIC HEALTH RELEVANCE: Myelodysplastic syndrome (MDS) is, at present, incurable preleukemic disease occurring most frequently among the elderly with about 14,000 new cases per year in the USA. About 30-40% of these cases progress to acute myeloid leukemia (AML). With an urgent need to improve therapy in this group, it is critical to generate effective modeling systems (including mouse models) for investigating the genetic lesions commonly observed in MDS and AML. However, the precise molecular mechanisms whereby genetic changes induce the progression of MDS to AML remain poorly understood. The proposed research focuses on an innovative mouse model for studying MDS progression and AML transformation. An important outcome of our research with this innovative mouse model lies in the potential for developing effective target therapies for MDS thus improving the prognosis for patients facing this incurable disease. Such an advancement presents significant benefits to public health by reducing the high rate of mortality associated with MDS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = -$24,600 )
2010	2009	NEVADA CANCER INSTITUTE	1000 WEST CHARLESTON BOULEVARD	LAS VEGAS	NV	89135	CLARK	USA	Cancer Biology Research	000	2	5/6/2010	NON-COMPETING CONTINUATION	-$184,505
2010	2009	SUNY, STONY BROOK	OFFICE OF RESEARCH SERVICES	STONY BROOK	NY	11794	SUFFOLK	USA	Cancer Biology Research	001	3	5/7/2010	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$159,905
														Subtotal = -$24,600

Issue Date FY: 2009 ( Subtotal = $243,000 )
2009	2009	NEVADA CANCER INSTITUTE	1000 WEST CHARLESTON BOULEVARD	LAS VEGAS	NV	89135	CLARK	USA	Cancer Biology Research	000	2	6/26/2009	NON-COMPETING CONTINUATION	$243,000
														Subtotal = $243,000

Issue Date FY: 2008 ( Subtotal = $202,500 )
2008	2008	NEVADA CANCER INSTITUTE	1000 WEST CHARLESTON BOULEVARD	LAS VEGAS	NV	89135	CLARK	USA	Cancer Biology Research	000	1	6/25/2008	NEW	$202,500
														Subtotal = $202,500

Grand Total All Awards = $420,900

Top

All Categories

About

Search

Reports

Data Submission

Award Information

FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION

Award Number: R21CA131522

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2008

PERIOD OF PERFORMANCE END DATE: 06/30/2011

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer